Narrative
Immunotherapy is revolutionising cancer treatment. University of Manchester (UoM) researchers have been at the forefront of developing a branch of immune-oncology, Adoptive Cell Therapy (ACT), through molecular and pre-clinical research to delivery within the NHS as standard-of-care treatment. Development and commercialisation of ACT products has led to economic impact, with the UoM spin-out company Immetacyte expanding from 40 employees in 2019 to merger with Instil Bio in 2020 (raising USD172,000,000 in financing). Worldwide, thousands of patients have now benefited from these life-saving treatments and in the UK alone, around 200 patients per year currently receive commercial products.| Impact date | 1 Aug 2013 → 31 Jul 2020 |
|---|---|
| Category of impact | Technological impacts, Health and wellbeing, Economic, Policy |
| Impact level | Adoption |
Research Beacons, Institutes and Platforms
- Cancer
Documents & Links
Related content
-
Research output
-
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells
Research output: Contribution to journal › Article › peer-review
-
Massively parallel interrogation and mining of natively paired human TCRαβ repertoires
Research output: Contribution to journal › Article › peer-review
-
The clinical efficacy of first generation carcinoembryonic antigen (CEACAM5) specific CAR T cells is limited by poor persistence and transient pre-conditioning dependent respiratory toxicity
Research output: Contribution to journal › Article › peer-review